Diseases

Stakeholder Insight: Metabolic Syndrome

Multiple definitions complicate treatment

Publication Date	April 2006
Publisher	Datamonitor
Product Type	Report
Pages	293
ISBN Number	not applicable
Product Code	DAT00123

Price

£5,740.00
approximately: $8,691 | €6,406

pdf

print £5,760 ($8,721 | €6,429)

Order above formats by FAX

Introduction

Datamonitor estimates that there are nearly 86 million Metabolic Syndrome patients in the six major markets. Although the patient pool in need of treatment for Metabolic Syndrome is large, the lack of an approved indication for Metabolic Syndrome, the lack of a consensus definition and the aversion of physicians to pharmacotherapy limit the size of the Metabolic Syndrome market, considerably

Scope

Determination of the prevalence of Metabolic Syndrome and its component conditions
Evaluation of physician awareness of Metabolic Syndrome and its importance, and of physician perceptions of treatment options for the condition
Assessment of the potential of existing drug classes and developmental compounds in the treatment of Metabolic Syndrome
Understanding of the critical issues affecting the Metabolic Syndrome market

Report Highlights

The lack of a consensus definition for Metabolic Syndrome is complicating the diagnosis and management of patients.
Lifestyle intervention may not be the most rational approach when treating Metabolic Syndrome patients.
The significant patient potential and unmet need characteristic to the Metabolic Syndrome market are counterbalanced by a significant number of challenges.

Reasons to Purchase

Target physicians more effectively, through an understanding of prescribing behavior and its influences
Assess the impact that the different definitions of the condition have in the management of Metabolic Syndrome
Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products

Chapter 1 Executive Summary
- Scope of the analysis
- Datamonitor insight into the Metabolic Syndrome market
- The lack of a consensus definition for Metabolic Syndrome is complicating the diagnosis and management of patients.
- The prevalence of Metabolic Syndrome is driven by the obesity epidemic. However, its great diversity makes it hard to identify treatment targets.
- Lifestyle intervention may not be the most rational approach when treating Metabolic Syndrome patients.
- The significant patient potential and unmet need characteristic to the Metabolic Syndrome market are counterbalanced by a significant number of challenges.
Chapter 2 Introduction And Scope
- Coverage of the Stakeholder Insight Survey
Chapter 3 Country Treatment Trees
- Introduction to the treatment trees
- US
- France
- Germany
- Italy
- Spain
- UK
Chapter 4 Definition Of Metabolic Syndrome
- Background
- Pre-diabetic population
- Metabolic Syndrome
- Confusion over syndrome name
- Disease definition
- Pathogenesis
- Clinical criteria for diagnosis
- Controversy surrounding definitions
- Metabolic Syndrome as a marker for cardiovascular disease
- Progression of Metabolic Syndrome to disease/events
- Insulin resistance and its associated conditions
- Insulin resistance and obesity
- Insulin resistance and aging
- Insulin resistance and dyslipidemia
- Insulin resistance and hypertension
- Insulin resistance and thrombosis
- Insulin resistance and advanced glycation end products
- Insulin resistance and the hepatic insulin-sensitizing substance effect
- Detection, screening and diagnosis - a topic of debate
- Diagnosis of insulin resistance
- Igt Versus Ifg
- Impact on drug development
- Who should be screened?
- Screening tests
- Other considerations
Chapter 5 Epidemiology Of Metabolic Syndrome
- Disease definition and classification
- Prevalence of Metabolic Syndrome
- Metabolic Syndrome prevalence methodology
- US
- France
- Germany
- Italy
- Spain
- UK
- Impaired fasting glucose prevalence
- Impaired fasting glucose prevalence methodology
- Dyslipidemia prevalence
- Hypercholesterolemia prevalence methodology
- US
- France
- Germany
- Italy
- Spain
- UK
- Hypertension prevalence
- Hypertension prevalence methodology
- US
- France
- Germany
- Italy
- Spain
- UK
- Obesity prevalence
- Obesity forecasts
- Obesity prevalence methodology
- US
- France
- Germany
- Italy
- Spain
- UK
- Forecast methodology
- Prevalence of obesity in juveniles
Chapter 6 Segmentation Of Metabolic Syndrome Patients
- Breakdown by demographic characteristics
- Breakdown by risk factor
- High risk patient profile
- Treatment guidelines
- Importance of treating Metabolic Syndrome
Chapter 7 Lifestyle Management Versus Pharmacological Treatment
- Management of Metabolic Syndrome
- Lifestyle Management
- Lifestyle management and clinical practice.
- Delayed diagnosis of Metabolic Syndrome
- Therapeutic Lifestyle Changes (TLC)
Chapter 8 Prescribing Trends
- Current role for pharmacological treatment
- Approaches to the pharmacological treatment of Metabolic Syndrome
- Overall prescribing trends
- Obesity
- Xenical
- The XENDOS study shows orlistat reduces risk of type 2 diabetes
- The FDA approves the use of orlistat in adolescents
- The European Commission approves label extension
- Meridia
- Behavior therapy and sibutramine for the treatment of adolescent obesity
- STORM trial shows weight-maintenance success after weight loss is positively influenced by sibutramine and leisure-time activity.
- Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome (PCOS)
- Sibutramine effective in the treatment of binge-eating disorder
- No benefits shown in health-related quality of life study in sibutramine-treated obese patients with type 2 diabetes
- SCOUT study
- Acomplia
- Clinical trial data
- Prescription trends
- Dyslipidemia
- Statins
- Ezetimibe
- Combination therapies
- Vytorin
- Caduet
- Fibrates
- Nicotinic acid derivatives
- Prescription trends
- Hypertension
- ARBs
- ACEIs
- Beta-blockers (BBs)
- Calcium-channel blockers (CCBs)
- Diuretics
- Prescription trends
- Diabetes
- Biguanides
- Sulfonylureas
- Thiazolidinediones
- Alpha glucosidase inhibitors
- Insulin
- Prandial Glucose Regulators
- Prescription Trends
- Pill Burden
- Metabolic Syndrome and disease prevention
- Insulin Resistance
- Obesity
- Awareness of developmental classes of compounds
Chapter 9 Critical Issues Affecting Metabolic Syndrome
- Unmet needs - Challenges
- Clinical unmet needs - challenges
- Consensus definition
- Efficacy goals not met by current treatment
- Need to curb the epidemic rise in the prevalence of Metabolic Syndrome.
- Avoiding compensatory feedback mechanisms
- Need to take advantage of synergies between drugs, diet, exercise and behavior
- If possible, address underlying cause(s) to the Metabolic Syndrome
- Commercial unmet needs-challenges
- Metabolic Syndrome not approved as indication
- Prevention of disease in 'healthy' subjects associated with higher demands on side effects and tolerability
- Safety
- Outcome studies will be required to demonstrate benefits of CVD and diabetes prevention
- Clinical trial issues
Appendix A Bibliography
- References
Appendix B Primary Research
- Physician research methodology
- Physician sample breakdown
- US
- France
- Germany
- Italy
- Spain
- UK
- Questionnaire
- 1. Patient Segmentation and Diagnosis
- 2. Treatment of Metabolic Syndrome
- 3. Future developments
- 4. Patient outcomes
- Disclaimer